Teva Drops Azilect Patent Claim Against Watson, Mylan

Law360, New York (July 14, 2011, 2:55 PM EDT) -- A New Jersey federal judge on Wednesday signed off on the dismissal of one of two infringement claims Teva Pharmaceutical Industries Ltd. had brought against Watson Laboratories Inc. and Mylan Inc. over patents for Teva’s Parkinson's disease drug Azilect.

Claims involving another patent remain pending after U.S. District Judge Claire Cecchi's order, entered after the parties notified the court of a voluntary dismissal.

Teva sued Watson, Mylan and Orchid Chemicals & Pharmaceuticals Ltd. in October, alleging that abbreviated new drug applications the companies had filed for...
To view the full article, register now.